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ABSTRACT
Background: β-agonists are frequently used as bronchodilators for asthma as not only a reliever but also a
controller, and their utility has increased with the development of long-acting β2 selective drugs. Although anti-
inflammatory effects of β2 selective-agonists have been reported in vitro, side effects on augmentation of air-
way hyperresponsiveness by chronic use of β2 selective-agonists have been described in several reports. In
this study, we investigated the effects of procaterol, a second-generation β2-agonist, on airway inflammation in
vivo using an antigen-specific murine model of asthma.
Methods: Mice immunized with ovalbumin (OVA) + alum and challenged with inhaled ovalbumin were orally
administered procaterol during the challenge. After inhalation, the mice were tracheostomized and placed in a
body box under controlled ventilation to measure airway resistance before and after acetylcholine inhalation.
Results: Administration of procaterol at a clinical dose equivalent did not augment airway hyperresponsive-
ness, inflammation of the airway wall, or subsequent airway wall thickening induced by OVA inhalation. BALF
cell analysis revealed that the eosinophil number in the BALF was significantly reduced in procaterol-treated
mice compared to untreated mice.
Conclusions: Oral administration of procaterol at a clinical dose did not augment airway responsiveness, but
did reduce eosinophil inflammation.
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INTRODUCTION
Currently, the main target of asthma therapies is
chronic airway inflammation.1-3 The steroid inhaler
has become a basic long-term therapy for manage-
ment of chronic airway inflammation.4 For combina-
tion therapy, steroid inhalers have been supple-
mented with long-acting β2 agonists, theophylline, or
leukotriene receptor agonists.5-7 Clinically, it has
been observed that addition of β2 selective-agonists is
more effective than doubling the dose of steroid in-
haler.4,8-10
Studies in vitro have demonstrated that β2
selective-agonists possess anti-inflammatory effects.
β2 selective-agonists increase cyclic AMP levels,
which in turn inhibit mast cell and eosinophil de-
granulation, induction of apoptosis, and cytokine pro-
duction.11-16 In contrast, human studies as well as in
vivo studies have shown that chronic use of β2 ago-
nists worsen airway hyperresponsiveness.17-19 The
anti-inflamma-tory effects of salmeterol, a new long-
acting β2 agonist, have been intensively studied.11,20-
22 Salmeterol shows superior anti-inflammatory activi-
ties over salbutamol,23 and in addition it possesses
synergistic effects with steroids.24-26 However, there
are contradictory data regarding the anti-
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inflammatory effects and the synergistic effects of sal-
meterol.27-29 In this study, we investigated the in vivo
effects of a clinical dose of procaterol on airway in-
flammation as well as on airway hyperresponsive-
ness. Procaterol is β2-selective full agonist that is
used as a rescue from asthmatic attack when inhaled
and as a controller when taken orally. We found that
a clinical oral dose of procaterol did not augment air-
way responsiveness. Rather, procaterol exhibited a
tendency to reduce eosinophil infiltration.
METHODS
MEASUREMENT OF SERUM PROCATEROL
CONCENTRATIONS
All mice were orally administered procaterol (Otsuka
Pharmaceutical Co. Ltd, Tokyo, Japan) dissolved in
distilled water at doses of 0.1, 1, or 10 mgkg in a vol-
ume of 10 mLkg. At 1 hour and 6 hours after admini-
stration, a venous blood sample was collected from
the large abdominal vein of mice anesthetized with
ether. The blood was transferred to a sample tube
and centrifuged at 3000 rpm for 30 minutes, and the
serum was frozen until analysis by liquid
chromatography-tandem mass spectrometry. Each
sample comprised sera obtained from 5 mice.
TREATMENT OF MICE
Specific pathogen-free male AJ mice (10―12 weeks
old) with native airway hyperresponsiveness to ace-
tylcholine (ACh)30,31 were purchased from SLC (Shi-
zuoka, Japan). Mice were bred in the animal facilities
of Teikyo University School of Medicine under Spe-
cific Pathogen-Free (SPF) conditions. Care and use of
the animals followed the guidelines of the “Principles
of Laboratory Animal Care” formulated by the Na-
tional Society for Medical Research.
The mice were initially immunized four times with
10 μg OVA + 2 mg alum on days 0, 28, 35, and 49.
ELISA titers of OVA-specific IgE were significantly
elevated after the immunizations as previously re-
ported.32 After immunization, the mice were divided
into four groups for administration of inhaled chal-
lenge from day 49 to day 63 (inhalation of 20 mgml
OVA for 10 minutes every other day, total 7 times):
(1) 0.9 M NaCl, (2) OVA, (3) OVA + procaterol
(orally) (4) OVA + dexamethasone (1 mgkg, intrape-
ritoneally). Procaterol in distilled water and dex-
amethasone was dissolved in saline and saline only
was administered as a control. Procaterol and dex-
amethasone were administered once a day, at 1 hour
before each OVA inhalation. Four to six mice were
used in each group for one experiment.
ASSESSMENT OF AIRWAY RESPONSIVENESS
Twenty-four hours after the final OVA inhalation, air-
way responsiveness was analyzed. The mice were
anesthetized with pentobarbital and were tra-
cheostomized. The animals were connected to a Har-
vard ventilator with 0.25 ml tidal volume and a respi-
ratory frequency of 120minute, as previously re-
ported,33 after which they were given an injection of
pancuronium bromide. Airway resistance (Raw) was
measured using a whole-body plethysmograph
(Buxco Electronics, Inc., Troy, NY). ACh was admin-
istered by ultra-nebulization for 3 minutes. Data were
expressed as [(Raw after inhalation of AChRaw be-
fore inhalation) ×100 (%)].
BALF CELL ANALYSIS AND HISTOLOGICAL EX-
AMINATION
BALF was obtained from selected mice by intubating
and washing the lungs with 1 ml of saline until the
recovered fluid reached 5 ml. BALF was centrifuged
at 1500 rpm for 10 minutes at 4℃. Pellets were dis-
solved in 1 ml PBS and the number of the cells was
counted. Cytospin specimen was obtained by rotating
at 640 rpm for 2 minutes. Then, the cells were stained
with Diff Quik (International Reagents Corporation)
and the cell differentiation counts were examined by
microscope.
The lungs were fully inflated using 10 cm H2O
pressure and fixed with 20% formaldehyde for
hematoxylin-eosin (HE) and elastica van Gieson
(EVG) staining.
ANALYSIS OF MRNA EXPRESSION
Lungs of mice were frozen in liquid nitrogen immedi-
ately after harvest and were used for RNA extraction.
Each lung tissue was moved quickly into 1 ml ISO-
GEN (Nippon Gene Co., Ltd., Tokyo, Japan). Lung
tissue was homogenized and total RNA was ex-
tracted, using a modified acid guanidium-phenol-
chloroform method. To synthesize cDNA, 5 μg of to-
tal RNA was incubated with 5 mM MgCl2, 1 mM
dNTP mixture, 0.25 U reverse transcriptase, 1 U RNase
inhibitor, and 0.125 μM oligo (dT) (Takara Biochemi-
cals, Tokyo, Japan). Amplification cycles were 42℃
for 15 minutes, 99℃ for 5 minutes, and then 5℃ for 5
minutes using a GeneAmp PCR system 9700 (Applied
Biosystems, Foster City, CA, USA).
The mRNA levels of cytokines were quantified by
real-time polymerase chain reaction (PCR) using the
Light Cycler-Fast Start DNA Master SYBR Green I
kit (Roche Diagnostics, Mannheim, Germany) for
amplification of cDNA. The reaction was undertaken
in 20 μl, containing 3 mM MgCl2, 1 μM primers,
FastStart Taq DNA polymerase, dNTP mix and SYBR
Green I (Light Cycler-Fast Start DNA Master SYBR
GreenI kit, Roche Diagnostics). Quantification was
performed with a standard curve obtained using 5 di-
lutions of cDNA. Results are shown as ratios of the
level of mRNAs standardized to the level of β-actin
mRNA. The primers used were as follows: β-actin 5’-
CCTGTATGCCTCTGGTCGTA-3’ 5’-CCATCTCCTG-
CTCGAAGTCT-3’ 260bp, IL-13 5’-GAGGAGCTGAG-
CAACATCAC-3’ 5’-GCAATATCCTCTGGGTCCTG-3’
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Table 1 Serum Procaterol Concentrations in A/J Strain 
Mice
Serum Concentrations of Procaterol 
(ng/mL)Dose of
Procaterol 6 hours after
administration
1 hour after
administration
0.032 0.2120.1 mg/kg
0.557 3.2721 mg/kg
4.09823.86110 mg/kg
Each value is the mean of 2 samples. Each sample com
prised serum obtained from 5 animals.
Fig. 1 Airway Responsiveness. Bronchoconstriction in-
duced with ACh inhalation. ACh 1.25, 2.5 5 mg/ml were in-
haled for 3 minutes. Raw was measured using whole body 
plethysmographs as described in the Methods. ACh-evoked 
changes in Raw are expressed as a percentage of Raw ob-
served before ACh inhalation (100%). Data shown are the 
mean ± SEM. (A) Dose response curve. ○OVA ▼ OVA ＋ 
procaterol● control mice (B) Airway responsiveness at 2.5 
mg/ml Ach.
A
%Raw 220
200
180
160
140
120
100
80
0 1.25 2.5 5 (mg/ml)
concentration of acetylcholine
B
%Raw2.5
180
160
140
120
100
 (n ＝ 6, each group)p ＜ 0.05
p ＜ 0.05
NS
Control OA OA
＋ procaterol
OA
＋ dexamethasone
157bp, eotaxin 5’-TCCCCAACACACTACTGAAG-3’ 5’-
AGGCTCTGGGTTAGTGTCAA-3’ 217bp, TGF-β1 5’-
AACAACGCCATCTATGAG-3’, 5’-ATTCCGTCTCCT-
TGGTT-3’ 294bp.
STATISTICAL ANALYSIS
Data were statistically analyzed by Student’s t-test
and ANOVA. Statistical significance was accepted at p
< 0.05.
RESULTS
INFLUENCE OF PROCATEROL ON AIRWAY HY-
PERRESPONSIVENESS
First, we tried to set the concentration of procaterol
at a clinical dose. A single clinical dose of procaterol
in humans reaches 0.2 ngmL of serum level.34,35 We
found that oral administration of 0.1 mgkg pro-
caterol reached the human effective serum concen-
tration (Table 1). Next, we examined whether con-
tinuous treatment with procaterol (0.1 mgkg) aug-
ments airway responsiveness. The dose response
curve was examined using three different mice in
each group as shown in Figure 1A. OVA inhalation
significantly increased airway responsiveness after
2.5 mg and 5 mg ACh inhalation (p < 0.05). Treat-
ment with procaterol before OVA inhalation did not
augment airway responsiveness under these condi-
tions (Figs. 1A, B). Because we examined airway hy-
perresponsiveness 25 hours after the final procaterol
administration, the direct effect of bronchodilation by
procaterol was negligible. We hypothesize that the
slight decrease in airway response by procaterol is at-
tributable to its influence on airway inflammation.
EFFECT OF PROCATEROL ON AIRWAY IN-
FLAMMATION
Next, we examined the influence of procaterol on air-
way inflammation. BALF cell analysis was performed
24 hours after the final inhalation of OVA. The total
number of cells in BALF was significantly increased
in OVA-treated groups compared with the non-
treated groups (p < 0.01). Macrophages were domi-
nant in non-treated groups. In contrast, an increase in
eosinophils was prominent in OVA-treated groups (p
< 0.01) (Fig. 2). A significant decrease in eosinophil
number was observed in OVA inhalation group (p <
0.05) (Fig. 2). We also performed histological exami-
nation with HE staining and EVG staining. Histologi-
cal analysis confirmed deceased infiltration of eosino-
phils in the submucosal area in procaterol-treated
mice (Fig. 3A). EVG staining showed that subepithe-
lial fibrosis, which represents airway remodelling, did
not worsen after procaterol treatment (Fig. 3B).
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Fig. 2 BALF Cel Analysis. Lungs were subjected to 
lavage through intubations until 5 ml of BALF was obtained. 
Cels present in the BALF were peleted, resuspended in 1 
mL of saline and placed on glass slides, where they were 
counted and fixed by Cytospin. Slides were then stained 
with Dif Quik, and cel diferentiation was assessed 
microscopicaly. Each bar indicates means ± SEM of seven 
mice.  □ Total cels　□ macrophage　■ eosinophils　■ 
lymphocytes.　Similar experiments were undertaken at 
least three times.
(×105cells)
140
120
100
80
60
40
20
0
Control OA OA
＋ procaterol
p ＜ 0.01 p ＜ 0.05
p ＜ 0.05p ＜ 0.01
Fig. 3 Histological Analysis. Hematoxylin eosin (A) and Elastica van Gie-
son staining (B) were performed on parafin-embedded sections. Lungs 
were extracted and fixed overnight with intra-tracheal infusion of 10% for-
malin maintaining the airway pressure at 10 cm H2O lung.
A
×400
×200
B
control OA OA ＋ procaterol
control OA OA ＋ procaterol
EFFECT OF PROCATEROL ON CYTOKINE
mRNA AND PROTEIN SYNTHESIS
β2 agonists have been reported to suppress cytokine
production in vitro. Next, we examined the effect of
procaterol on cytokine mRNA synthesis in vivo. Fig-
ure 4 shows that procaterol itself did not significantly
reduce IL-13 and eotaxin mRNA, the products of
which mediate eosinophil-associated inflammation.
TGF-β, which is involved in airway remodelling, also
exhibited no change after procaterol administration.
DISCUSSION
β2 selective agonists function as bronchiodilators and
are used as relievers and controllers.34,35 Recently, in-
haled steroids have been recognized as the most ef-
fective anti-inflammatory drugs and are the most
common choice for controlling asthma.36 A combined
therapy comprising inhaled steroids and a long acting
β2 selective agonist is recommended for controlling
asthma.25 Synergistic effects have been reported, and
in fact, the combined therapy is more effective than
doubling the dose of inhaled steroids.4,8-10 Thus new
aspects of the usefulness in β2 selective agonists are
considered. However, the adverse effects of chronic
Effect of Procaterol on Airway Inflammation
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Fig. 4 Efect of Procaterol on IL-13, Eotaxin and TGF-β Gene Expression. RNA was 
extracted from whole lung of OVA treated mice and mRNA expression for various 
genes was determined by real-time PCR. Data are mean ± SEM of three diferent mice.
control
105
104
103
102
105
104
103
102
104
103
102
control OAOA OA ＋
procaterol
OA ＋
procaterol
control OA OA ＋
procaterol
IL-13
NS
NS
eotaxin TGF-β
/β-actin p ＜ 0.01
p ＜ 0.05 NSp ＜ 0.05
use by inhalation, including increases in airway hy-
perresponsiveness, have been reported.17,37,38 The
short acting β2 selective agonist, salubutamol, has
been shown to worsen the airway hyperresponsive-
ness in animal model and in human studies.17-19,37-39
While the anti-inflammatory activities of salmeterol, a
long acting β2 selective agonist have been re-
ported,11,13,23 some reports deny the effects.27,28 In
this study, we investigated the effect of procaterol, a
β2 selective full agonist, which is commonly used as
controller by oral tablet administration. We found
that clinical dose of oral procaterol did not augment
airway responsiveness and airway remodelling.
Rather, procaterol significantly reduced eosinophil in-
filtration.
Mast cells, eosinophils, and smooth muscle cells at
the site of asthmatic inflammation possess β2 recep-
tors,40 and β2 agonists have been reported to block
mast cell and eosinophil degranulation.13,14 β2 ago-
nists function by increasing the concentration of in-
tracellular cAMP,41 which result in inhibition of cy-
tokine synthesis and induction of apoptosis on
eosinophils in vitro.42 However, a report which stud-
ied spontaneous apoptosis showed that β2 agonists
and cAMP increasing reagents decrease apoptosis of
eosinophils.43 In contrast to spontaneous apoptosis, it
has been shown that cytokine mediated survival of
eosinophils is inhibited by the increase of cAMP,
through accelerated induction of apoptosis.16,44 Theo-
phylline, another cAMP increasing drug, has been
shown to reduce cytokine mediated eosinophil sur-
vival, which is relevant to the in vivo condition.45-47
We can hypothesize that the in vivo effects of a de-
crease in eosinophils occurred via induction of apop-
tosis. Another possible mechanism of a decrease in
airway inflammation by procaterol is down-regulation
of adhesion. Procaterol has been proven to reduce ad-
hesion molecules in vitro studies.16,48 It was also re-
ported that systemic administration of tulobuterol, a
β2 selective agonist, attenuates eosinophil adhesion
to endothelial cells, which results in reduction of
eosinophil inflammation.49 Systemic but not inhala-
tional administration can modulate endothelial cells.49
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